SARS-CoV-2 Glycosylation Suggests That Vaccines Should Have Adopted the S1 Subunit as Antigen | Zendy

Ariel Fernández | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

SARS-CoV-2 Glycosylation Suggests That Vaccines Should Have Adopted the S1 Subunit as Antigen

Author(s) -

Ariel Fernández

Publication year - 2021

Publication title -

acs pharmacology and translational science

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.271

H-Index - 10

ISSN - 2575-9108

DOI - 10.1021/acsptsci.1c00036

Subject(s) - epitope , protein subunit , virology , antigen , immune system , antibody , glycosylation , biology , virus , immunology , genetics , gene

Extant SARS-CoV-2 vaccines use the trimeric spike (S) protein as antigen. In the virus, the spike region is extensively glycosylated, modulating immune surveillance. Because they have been defused, many epitopes in the vaccine sidetrack the immune response. Only the receptor binding domain within the S1 subunit is well-exposed to antibody recognition. After proteolytic virus activation, the S1 subunit offers additional epitopes with antibody exposure. Thus, vaccines adopting the S1 subunit as antigen would have been more efficacious than the existing ones.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research